MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Articles

Pharmalicensing brings you advice, commentary and analysis from industry experts.

Articles

Displaying 1..10 of 10 - per page
Order by
The University of California at San Francisco claims credit for identification of the DNA of the human growth hormone. Genentech was alleged to have taken and used the University's actual DNA invention without permission. More
Synthetic biology is a new discipline that brings together engineering, biology, chemistry, and information technology to take genetics and genomics to the next level. More
The principle that genetic material is 'property' in the intellectual property law sense was established in the 19th century. This two part article looks at some developments in bio-intellectual property rights over the last 50 years. More
The answer to the question whether gene and compound per se claims provide an appropriate reward lies at the heart of the patent system. More
The article challenges views that current patent legislation is inadequate to cover developments in the biological field. More
The first part of this article charted developments in bio-IPRs from the Paris Convention in 1883 through to the end of the 1970s. Part two will look at developments from the 1980s through to today. More
A Critical Analysis of the (Non)-Patentability of Diagnostic Methods and Consequences For BRCA1 Gene Type Patents in Europe More
Despite the arrival of the first commercialized cancer treatment, the road to generalized therapeutics remains hazardous. More
Professor Alan Kingsman discusses the development of Oxford BioMedica from a spin-out from his Oxford University lab to a company listed on the LSE. More
This article is based on some of the findings of a research study ethical issues related to the commercial implementation of new technologies undertaken during the preparation of the Nuffield Bioethics Council Report on Genetically-modified Crops More
Displaying 1..10 of 10 - per page
Order by

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us